If you read between the lines, that is what Ian Hudson, the UK’s Chief Executive of the Medicines and Healthcare products Regulatory Agency is saying. In a statement released this week, he cites “I feel the time is right for a new person to guide the Agency and our work through its next phase, following the UK’s departure from the EU next year.” Hard to critique that rationale. He’s also not alone. A recent study from GlobalData shows that “59% of healthcare industry professionals in the UK indicated their sentiment on the impact of Brexit has become more negative over the past 3 months.” The Financial Times recently published some “startling” Brexit economic scenarios and Prime Minister Theresa May had to say very recently that it was not possible to hold a second Brexit referendum before Britain leaves the EU in March. Cheerio.